Results 1 to 2 of 2

Thread: new osteoporosis drug stimulates bone growth

  1. #1

    new osteoporosis drug stimulates bone growth

    TORONTO, Sept 12 (Reuters) - Shares of Canadian biotech Theratechnologies Inc. (Toronto:TH.TO - News) jumped as much as 8 percent on Thursday after the company announced positive test results for its hormone patch system to help strengthen brittle bones in post-menopausal women.


    Montreal-based Theratechnologies said its therapy, which could become commercially available in four to five years, has widespread application. Nearly 36 million women across Europe, Japan and North America suffer from severe osteoporosis.

    "Our (treatment) stimulates the formation of bone," Luc Tanguay, president and chief executive of Theratechnologies told Reuters.

    "All the drugs that are currently on the market to treat osteoporosis are not able to make a new bone," he added.

    Theratechnologies' tests conducted on animals showed that its hormone therapy can be delivered through a patch, developed by Alza Corp., maker of the Nicoderm patch used to help people quit smoking.

    Alza, a subsidiary of Johnson & Johnson (NYSE:JNJ - News), is using its technology to deliver a hormone that regulates the amount of calcium and phosphates in the body.

    "Assuming an injectable form of (this hormone) will be launched commercially in 2003, we feel there will be a strong need for a more patient-friendly form available through a patch," said Thierry Abribat, Theratechnologies' chief scientific officer.

    Tanguay said Theratechnologies could either develop the treatment by itself or through a partner.

    Under its agreement with Alza, Theratechnologies is responsible for the developing the treatment and holds the marketing rights.

    Theratechnologies shares closed unchanged at C$5.65 on the Toronto Stock Exchange. Earlier in the session, they reached C$6.20.

    The shares have fallen more than 50 percent this year, underperforming the Toronto Stock Exchange's health care subindex, which has dropped 31 percent in the same period.

  2. #2

    For SCI

    For those with SCI, the only studies that have shown any benefit from use of these drugs in people with SCI are when they were combined with an aggressive suspended ambulation/FES program. Without this added intervention, the drugs had no effect on osteoporosis.


Posting Permissions

  • You may not post new threads
  • You may not post replies
  • You may not post attachments
  • You may not edit your posts